Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Анапластическая крупноклеточная лимфома взрослых: влияние прогнозтических факторов на терапию
Анапластическая крупноклеточная лимфома взрослых: влияние прогнозтических факторов на терапию
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–58.
2. Stein H, Foss HD, Durkop H et al. CD 30+ anaplastic large-cell lymphoma a revive of its histopathologic, genetic, and clinical features. Blood 2000; 96 (12): 3681–95.
3. Durkop H, Latza U, Hummel M et al. Molecular cloning and expression of new member of the herve drowth factor receptor family that is characteristic for Hodgkin disease. Cell 1992; 68: 421.
4. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697–706.
5. Williams DM, Hobson R, Imeson J et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812–20.
6. Seidemann K, Tiemann M, Schrappe M et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699–706.
7. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–6.
2. Stein H, Foss HD, Durkop H et al. CD 30+ anaplastic large-cell lymphoma a revive of its histopathologic, genetic, and clinical features. Blood 2000; 96 (12): 3681–95.
3. Durkop H, Latza U, Hummel M et al. Molecular cloning and expression of new member of the herve drowth factor receptor family that is characteristic for Hodgkin disease. Cell 1992; 68: 421.
4. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697–706.
5. Williams DM, Hobson R, Imeson J et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812–20.
6. Seidemann K, Tiemann M, Schrappe M et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699–706.
7. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–6.
Авторы
А.А.Семенова, Е.Н.Сорокин, И.В.Поддубная, Н.А.Пробатова, О.Л.Тимофеева
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.